Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0011854 (type 1 diabetes)
 20,749 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

A campaign against hepatitis B was launched in 1985 in Latium Region, Italy, aimed at hospital workers, newborns of HBsAg positive mothers, hemodialysis patients, thalassemics and hemophiliacs. Subsequently, since the beginning of 1987 other at risk categories were included, namely households of HBsAg positive carriers, subjects with accidental exposure to Hepatitis B virus (HBV) (i.e exposure to street syringes), health care personnel working outside the hospital setting such as dentists, private clinics and laboratory workers, etc. A protocol was defined by the Regional Epidemiologic Unit (Osservatorio Epidemiologico Regionale) in order to evaluate the immunogenicity and safety af the two plasma-derived (pd) vaccines registered in Italy, MSD and Pasteur, in field conditions. Subjects belonging to these at risk categories were distributed among 21 hospital based vaccination units, to which the two vaccines were randomly allocated. Subjects were considered eligible for vaccination if they were HBsAg negative and Anti-HBs negative or Anti-HBs positive at low titer i.e. less than 20 milli-International units per milliliter. Subjects with insulin dependent diabetes, chronic liver disease or known hypersensitivity to vaccine components were also excluded. Antibody response was checked at six months since the beginning of the vaccination, i.e. after two doses of the MSD and three doses of Pasteur vaccine and expressed in miU/ml by use of Hollinger formula. Pre-vaccination screening, vaccination and post-vaccination anti-HBs testing were offered free of charge.(ABSTRACT TRUNCATED AT 250 WORDS)
 ...
PMID:[Vaccination against hepatitis B: 3 years' experience at the Latium Operative Unit]. 248 67

In order to provide better therapy we strive to increase our knowledge of how the immune system behaves and communicates in common pediatric immunological diseases, such as type 1 diabetes, allergic and celiac diseases. However, when dealing with pediatric diseases, where study subjects are almost exclusively children, blood volumes available for immunological studies are limited and as such must be carefully handled and used to their full extent. Single immune markers can easily be detected by a traditional Enzyme Linked Immunosorbent Assay (ELISA), whereas multiple markers can be detected by a fluorochrome (Luminex) or electrochemiluminescence (MSD) technique. These techniques however are sometimes not sensitive enough to detect low levels of secreted immune markers in limited sample sizes. To detect immune markers at the single-cell level, an Enzyme Linked Immuno-spot (ELISPOT) can be used to pin-point elusive immune markers in common pediatric immunological diseases.
...
PMID:Enzyme linked immuno-spot; a useful tool in the search for elusive immune markers in common pediatric immunological diseases. 2471 Apr 20